tradingkey.logo
tradingkey.logo
Search

Airsupra® (Albuterol/Budesonide) Us Prescribing Information Updated To Reflect The Statistically Significant Severe Exacerbation Risk Reduction In Patients With Mild Asthma Compared With Albuterol

ReutersSep 18, 2025 1:26 PM
facebooktwitterlinkedin

AstraZeneca PLC AZN.L:

  • AIRSUPRA® (ALBUTEROL/BUDESONIDE) US PRESCRIBING INFORMATION UPDATED TO REFLECT THE STATISTICALLY SIGNIFICANT SEVERE EXACERBATION RISK REDUCTION IN PATIENTS WITH MILD ASTHMA COMPARED WITH ALBUTEROL

  • ASTRAZENECA PLC - FDA APPROVES SUPPLEMENTAL NEW DRUG APPLICATION FOR AIRSUPRA

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI